Inactive Instrument

Analyst Reco. Accretive Health, Inc. Nyse

Equities

US00438V1035

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 18	R1 RCM's Q1 Results to Focus on Strategic Alternatives, Change Cyberattack, RBC Says	MT
Apr. 11	North American Morning Briefing : Stock Futures -2-	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

KeyBanc Downgrades R1 RCM to Sector Weight From Overweight on Potential Risks to Hospital End Markets	Apr. 10	MT
Canaccord Genuity Trims Price Target on R1 RCM to $16 From $17, Maintains Buy Rating	Mar. 20	MT
Citigroup Upgrades R1 RCM to Buy From Neutral, Price Target is $16	Mar. 20	MT
Truist Securities Downgrades R1 RCM to Hold From Buy, Price Target is $16	Mar. 05	MT
KeyBanc Raises Price Target on R1 RCM to $17 From $13, Maintains Overweight Rating	Feb. 29	MT
Barclays Downgrades R1 RCM to Equalweight From Overweight, Price Target is $14	Feb. 28	MT
Evercore ISI Downgrades R1 RCM to In Line From Outperform, Raises Price Target to $16 From $12	Feb. 28	MT
Deutsche Bank Downgrades R1 RCM to Hold From Buy, $15 Price Target	Feb. 27	MT
Deutsche Bank Trims R1 RCM Price Target to $15 From $16, Maintains Buy Rating	Feb. 26	MT
Leerink Partners Initiates R1 RCM at Outperform Rating With $14 Price Target	Feb. 26	MT
TD Cowen Cuts R1 RCM Price Target to $20 From $26, Maintains Outperform Rating	Jan. 18	MT
Morgan Stanley Upgrades R1 RCM to Overweight From Equalweight, Trims Price Target to $17 From $17.50	Dec. 15	MT
JPMorgan Downgrades R1 RCM to Neutral From Overweight, Cuts Price Target to $11 From $20	Dec. 13	MT
Deutsche Bank Adjusts R1 RCM Price Target to $16 From $19, Maintains Buy Rating	Dec. 07	MT
Deutsche Bank Cuts R1 RCM Price Target to $19 From $22, Maintains Buy Rating	Nov. 14	MT
KeyBanc Adjusts R1 RCM Price Target to $18 From $20, Maintains Overweight Rating	Nov. 03	MT
RBC Cuts Price Target on R1 RCM to $19 From $22, Keeps Outperform Rating	Nov. 03	MT
Truist Securities Upgrades R1 RCM to Buy From Hold, Price Target is $18	23-10-19	MT
Cantor Fitzgerald Initiates R1 RCM at Overweight	23-08-15	MT
Deutsche Bank Adjusts R1 RCM Price Target to $22 From $18, Maintains Buy Rating	23-08-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Accretive Health, Inc. Nyse

Equities

US00438V1035

Analyst Reco.

Filters